Trial Outcomes & Findings for Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP) (NCT NCT01511068)

NCT ID: NCT01511068

Last Updated: 2023-08-30

Results Overview

A modified Bruce protocol stress test was used to evaluate improvement in blood oxygen saturation (SpO2). A pulse-oximeter was placed on the participant's finger with the participant at rest while sitting in a chair. Leads for the electrocardiograph were placed on the chest wall. The treadmill was started at 1.7 miles per hour (mph) and a grade of 0%. At three minute intervals, the speed increased as follows: 1.7 mph, 1.7 mph, 1.7 mph, 2.5 mph, 3.4 mph, 4.2 mph, 5.0 mph, 5.5 mph, 6.0 mph, 6.5 mph, 7.0 mph, and 7.5 mph. The participant stopped the test due to intolerable dyspnea or if the SpO2 fell below 88%.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

2 participants

Primary outcome timeframe

Baseline, 7 months

Results posted on

2023-08-30

Participant Flow

Participant milestones

Participant milestones
Measure
Inhaled Leukine (rhGM-CSF)
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Overall Study
STARTED
2
Overall Study
COMPLETED
2
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Age, Categorical
<=18 years
2 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Sex: Female, Male
Female
2 Participants
n=99 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
2 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=99 Participants
Race (NIH/OMB)
White
2 Participants
n=99 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
Region of Enrollment
United States
2 participants
n=99 Participants

PRIMARY outcome

Timeframe: Baseline, 7 months

A modified Bruce protocol stress test was used to evaluate improvement in blood oxygen saturation (SpO2). A pulse-oximeter was placed on the participant's finger with the participant at rest while sitting in a chair. Leads for the electrocardiograph were placed on the chest wall. The treadmill was started at 1.7 miles per hour (mph) and a grade of 0%. At three minute intervals, the speed increased as follows: 1.7 mph, 1.7 mph, 1.7 mph, 2.5 mph, 3.4 mph, 4.2 mph, 5.0 mph, 5.5 mph, 6.0 mph, 6.5 mph, 7.0 mph, and 7.5 mph. The participant stopped the test due to intolerable dyspnea or if the SpO2 fell below 88%.

Outcome measures

Outcome measures
Measure
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test
Participant 1
17 Percent Change
Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test
Participant 2
33 Percent Change

PRIMARY outcome

Timeframe: Baseline, 7 months

A modified Bruce protocol stress test was used to evaluate improvement in blood oxygen saturation (SpO2). A pulse-oximeter was placed on the participant's finger with the participant at rest while sitting in a chair. Leads for the electrocardiograph were placed on the chest wall. The treadmill was started at 1.7 miles per hour (mph) and a grade of 0%. At three minute intervals, the speed increased as follows: 1.7 mph, 1.7 mph, 1.7 mph, 2.5 mph, 3.4 mph, 4.2 mph, 5.0 mph, 5.5 mph, 6.0 mph, 6.5 mph, 7.0 mph, and 7.5 mph. The participant stopped the test due to intolerable dyspnea or if the SpO2 fell below 88%.

Outcome measures

Outcome measures
Measure
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Change in Minimum Pulse Oximetry During a Standardized Treadmill Exercise Test
Participant 1
0 Percent Change
Change in Minimum Pulse Oximetry During a Standardized Treadmill Exercise Test
Participant 2
-2.1 Percent Change

SECONDARY outcome

Timeframe: Baseline, 7 months

Routine full pulmonary function testing, including spirometry, lung volumes, and DLCO, were performed according to American Thoracic Society guidelines.

Outcome measures

Outcome measures
Measure
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Change in Diffusion Capacity for Carbon Monoxide
Participant 1
11 Percent Change
Change in Diffusion Capacity for Carbon Monoxide
Participant 2
4 Percent Change

SECONDARY outcome

Timeframe: Baseline, 7 months

Standardized exercise pulse oximetry (SEPO) was used to measure SpO2 at the participant's home on a weekly basis between clinic visits. Briefly, a pulse-oximeter was placed on the finger with the participant at rest sitting in a chair. Three baseline (resting) readings were taken over a period of 1 minute to measure the SpO2 at rest. The participant then began stepping onto and off of the first step of a staircase in the home while holding onto the handrail for safety. Stepping was started by placing the bottom of one foot onto the stair followed by the other foot and then removal of one foot from the stair to the floor followed by the other foot. This procedure was repeated at a frequency of 1 cycle per second for a total of 5 minutes. The participant's parent assisted by noting the saturation data at 1-minute intervals during the test onto the weekly exercise form in the participant's Diary. The participant's saturation data continued to be recorded for 3 minutes after the test.

Outcome measures

Outcome measures
Measure
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Change in Minimum Pulse Oximetry During a Standardized Exercise Protocol Oximetry
Participant 1
0 Percent Change
Change in Minimum Pulse Oximetry During a Standardized Exercise Protocol Oximetry
Participant 2
50 Percent Change

SECONDARY outcome

Timeframe: Baseline, 7 months

High resolution computed tomography (HRCT) scans were performed using an interval technique, a 1 mm slice was obtained every 20 mm. The slice series were placed so that images were obtained from the pulmonary apices to the lung bases with one of the images located at the level of the carina. The CT parameters were performed at full inspiration and required a lower dose than usual clinical CT scans; 1 mm slices at 20 mm intervals,120 kVp, 60 mAs, rotation time 0.5 second. Images were reconstructed with lung and soft tissue reconstruction kernels (B35F and B60F). The primary analysis was performed using the B60F kernel. Images were read and reported according to Radiology Department protocol. The raw data was recorded on a DVD and sent to CCHMC for centralized reading and lung attenuation analysis.

Outcome measures

Outcome measures
Measure
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Change in Radiographic Evidence of PAP Lung Disease
Participant 1-Right Lung Baseline
-510 Hounsfield Units
Change in Radiographic Evidence of PAP Lung Disease
Participant 1- Right Lung End of Treatment
-579 Hounsfield Units
Change in Radiographic Evidence of PAP Lung Disease
Participant 1-Left Lung Baseline
-366 Hounsfield Units
Change in Radiographic Evidence of PAP Lung Disease
Participant 1-Left Lung End of Treatment
-441 Hounsfield Units
Change in Radiographic Evidence of PAP Lung Disease
Participant 2-Right Lung Baseline
-593 Hounsfield Units
Change in Radiographic Evidence of PAP Lung Disease
Participant 2-Right Lung End of Treatment
-675 Hounsfield Units
Change in Radiographic Evidence of PAP Lung Disease
Participant 2-Left Lung Baseline
-630 Hounsfield Units
Change in Radiographic Evidence of PAP Lung Disease
Participant 2-Left Lung End of Treatment
-726 Hounsfield Units

SECONDARY outcome

Timeframe: Baseline, 7 months

The PedsQL quality of life questionnaire is a modular approach to measure health-related quality of life in healthy children and those with acute and chronic health conditions. It is self-administered and completed in less than 5 minutes. It contains 23 items divided into 4 domains: physical functioning, emotional functioning, social functioning, and school functioning. To reverse score, transform the 0-4 scale items to 0-100 as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate a better Health-Related Quality of Life.To create the Psychosocial Health Summary Score, the mean is computed as the sum of the items over the number of items answered in the Emotional, Social, and School Functioning Scales. The Physical Health Summary Score is the same as the Physical Functioning Scale Score. To create the Total Scale Score, the mean is computed as the sum of all the items over the number of items answered on all the Scales.

Outcome measures

Outcome measures
Measure
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Change in Quality of Life
Participant 1 -Total Score
10.7 Percent Change
Change in Quality of Life
Participant 1 - Physical Health Score
75 Percent Change
Change in Quality of Life
Participant 1 - Psychosocial Score
-5.2 Percent Change
Change in Quality of Life
Participant 1 - Parent Score
19.6 Percent Change
Change in Quality of Life
Participant 1 - Child Score
3.1 Percent Change
Change in Quality of Life
Participant 2 - Total Score
11.7 Percent Change
Change in Quality of Life
Participant 2 - Physical Health Score
7.4 Percent Change
Change in Quality of Life
Participant 2- Psychosocial Score
14.5 Percent Change
Change in Quality of Life
Participant 2 - Parent Score
5.6 Percent Change
Change in Quality of Life
Participant 2 - Child Score
18.2 Percent Change

SECONDARY outcome

Timeframe: Baseline, 7 months

The dyspnea visual analogue scales were used by the patient to record the level of dyspnea by a single mark on a linear scale. The dyspnea scale ranged from 0 to 10, with short of breath all the time equal to 0 and never short of breath equal to 10. A higher score indicated a better dyspnea score.

Outcome measures

Outcome measures
Measure
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Change in Dyspnea Symptom Score
Participant 1
71 Percent Change
Change in Dyspnea Symptom Score
Participant 2
11 Percent Change

SECONDARY outcome

Timeframe: Baseline and monthly up to 7 months

Serum GM-CSF autoantibody was measured as follows: microtiter plates were incubated (4°C, overnight) with rhGM-CSF, washed in PBS and Tween-20, and incubated (room temperature (RT), 1 hour) with blocking solution. Serum samples were diluted with dilution buffer and aliquots of diluted serum or standard were pipetted into adjacent microtiter wells, incubated at RT for 40 minutes, and then washed with wash buffer. Horseradish peroxidase-conjugated secondary antibody was diluted with dilution buffer and pipetted into each well. Plates were incubated (RT, 0.5 hour) and then washed with wash buffer. Substrate solution was added to each well, plates were incubated (RT, 15 min), and color development was stopped with sulfuric acid. Absorbance at 450 nm was measured using a Benchmark® ELISA plate reader.

Outcome measures

Outcome measures
Measure
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 0-Baseline
0.67 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 1-Begin Low Dose Therapy
0.36 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 2
0.32 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 3
1.85 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 4
19.7 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 5-Begin High Dose Therapy
71.8 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 6
118.1 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 7
128.2 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 8 - End of Therapy
110.7 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Baseline
0.551 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Begin Therapy
0.358 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 2
0.299 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 3
81.04 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 4
132.52 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 5-Begin High Dose Therapy
123.66 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 6
116.82 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 7
104.36 micrograms/ml
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 8 - End of Therapy
91.92 micrograms/ml

SECONDARY outcome

Timeframe: Baseline and monthly up to 7 months

Serum GM-CSF was measured via a commercial ELISA kit from R \& D Systems.

Outcome measures

Outcome measures
Measure
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 0-Baseline
43.75 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 1-Begin Low Dose Therapy
39.4 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 2
43.2 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 3
88.5 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 4
11.5 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 5-Begin High Dose Therapy
7.8 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 6
7.8 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 7
7.8 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 8 - End of Therapy
7.8 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 2-Baseline
26.8 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 2-Begin Therapy
27.9 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 2
24.8 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 3
7.8 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 4
7.8 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 5-Begin High Dose Therapy
7.8 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 6
7.8 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 7
7.8 picograms/ml
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 8 - End of Therapy
7.8 picograms/ml

SECONDARY outcome

Timeframe: Baseline and monthly up to 7 months

Surfactant protein D (SP-D) was measured via a commercial ELISA kit from Biovender.

Outcome measures

Outcome measures
Measure
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 0-Baseline
796.2 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 1-Begin Low Dose Therapy
619 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 2
696.4 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 3
589 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 4
697.2 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 5-Begin High Dose Therapy
536.9 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 6
642.4 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 7
495.9 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 8 - End of Therapy
673.2 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Baseline
618.7 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Begin Therapy
469.6 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 2
425.5 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 3
381.3 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 4
401.1 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 5-Begin High Dose Therapy
298.2 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 6
422 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 7
456.8 nanograms/ml
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 8 - End of Therapy
593 nanograms/ml

Adverse Events

Inhaled Leukine (rhGM-CSF)

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Inhaled Leukine (rhGM-CSF)
n=2 participants at risk
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Respiratory, thoracic and mediastinal disorders
Upper Respiratory Tract Infection
100.0%
2/2 • Number of events 2 • Adverse events were collected from the time of consent until the of completion of the study, approximately 1 year.
General disorders
Noseblood
50.0%
1/2 • Number of events 1 • Adverse events were collected from the time of consent until the of completion of the study, approximately 1 year.

Additional Information

Dr. Bruce Trapnell

Cincinnati Children's Hospital Medical Center

Phone: 513636-6361

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place